Heidelberg Pharma AG/€HPHA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Heidelberg Pharma AG
Heidelberg Pharma AG is a biotechnology company focused on developing novel cancer therapies. It specializes in a proprietary technology known as Antibody Targeted Amanitin Conjugates (ATACs), aimed at delivering potent toxins specifically to cancer cells. Founded in Germany, the company is headquartered in Ladenburg and operates primarily in the pharmaceutical sector, with a strong emphasis on research and development collaborations. Heidelberg Pharma positions itself by leveraging its unique ATAC platform, differentiating itself through targeted cancer treatment modalities. The company collaborates with pharmaceutical firms to enhance its development pipeline and commercial reach across various markets. Sources:
https://www.heidelberg-pharma.com/
Ticker
€HPHA
Sector
Primary listing
XETRA
Employees
60
Headquarters
Website
HPHA Metrics
BasicAdvanced
€122m
-
-€0.87
0.74
-
Price and volume
Market cap
€122m
Beta
0.74
52-week high
€5.12
52-week low
€2.32
Average daily volume
5.1k
Financial strength
Current ratio
2.395
Quick ratio
1.289
Long term debt to equity
-0.511
Total debt to equity
-0.511
Interest coverage (TTM)
-11,393.47%
Profitability
EBITDA (TTM)
-46.055
Gross margin (TTM)
81.28%
Net profit margin (TTM)
-1,261.93%
Operating margin (TTM)
-1,448.08%
Effective tax rate (TTM)
-2.65%
Revenue per employee (TTM)
€50,000
Management effectiveness
Return on assets (TTM)
-69.71%
Return on equity (TTM)
-820.00%
Valuation
Price to revenue (TTM)
38.067
Price to book
-8.06
Price to tangible book (TTM)
-5.09
Price to free cash flow (TTM)
-4.184
Free cash flow yield (TTM)
-23.90%
Free cash flow per share (TTM)
-0.621
Growth
Revenue change (TTM)
-53.03%
Earnings per share change (TTM)
92.76%
3-year revenue growth (CAGR)
-45.49%
10-year revenue growth (CAGR)
3.59%
3-year earnings per share growth (CAGR)
22.45%
10-year earnings per share growth (CAGR)
2.36%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
FAQs